Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst

Merck & Co Inc acquires CN201, a promising bispecific antibody for B-cell diseases, from Curon Biopharmaceutical for $1.3 billion. CN201 shows potential in treating malignancies and autoimmune diseases.